In a decision that gives at least some merit to Amgen Inc.'s interpretation of the patent dance laid out in the Biologic Price Competition and Innovation Act (BPCIA), the Federal Circuit this week granted the innovator biologics maker an injunction preventing, for the time being, the launch of the first FDA-approved biosimilar.